Antoine Papiernik

After we invested, I'll tell you.

Well, last time he said, no, no, no, I'm not going to, and I'm done.

And then he managed to convince to, you know, in French you say never two without three.

So three, you know, to go from three to four might be more complicated.

And, you know, he still has a lot of work to do on that.

No, I'm just saying, of course, experienced management who's done it before.

There's a lot of people in the US.

But, you know, Marc happens to be French, so we should rejoice that this is possible, even with people... Of course, there was a first time for him, right?

Look, I think you're absolutely right.

We believe that not just bispecific, but multispecifics is the way to go.

In fact, it's intuitively understandable why this would be better.

Poof is in the pudding, as I said earlier.

But we are, in fact, massively looking at this in both oncology as well as INI, immunology, information.

We think this approach in those two areas is going to be a major win going forward.

But it's not the only thing.

ADCs, I think the next-gen ADCs are going to be super important.

The next-gen radiopharmaceuticals are going to be super important.

We are the states today, if you look back and you leverage this knowledge for the future indications, just take those three modalities, multispecifics, ADCs, radiopharmaceuticals.

I would say...

I would not be surprised that 50% of all drugs in oncology and INI will be using one of those.